Combined vaccines--the European contribution.
Efforts to develop new vaccine combining as many immunogens as possible have stimulated researchers of most European vaccine manufacturers to contribute with new vaccine designs. Besides the conventional combinations the following approaches are under development: new carrier systems for inactivated antigens; new adjuvants for subunit antigens; live attenuated combined vaccines; vector combined vaccines; synthetic polypeptide combined vaccines. The availability of new combined vaccines will greatly facilitate immunization programmes for the control of many diseases around the world. The whole of modern society in general is moving towards prevention--for example on safety issues--as well as in medicine, where prophylactic approaches are medically, scientifically, ethically, and mortally more justifiable as well as being more cost-effective. Besides improving the health and overall quality of life of the world's population, the use of combined vaccines will further reduce already overstretched health care budgets.
Glück
R
R
Swiss Serum & Vaccine Institute, Berne.
D000276:Adjuvants, Immunologic; D002648:Child; D002675:Child, Preschool; D005060:Europe; D005822:Genetic Vectors; D006801:Humans; D007223:Infant; D012449:Safety; D014613:Vaccines, Attenuated; D017778:Vaccines, Combined / Q000191:economics
D000276:Adjuvants, Immunologic; D014613:Vaccines, Attenuated; D017778:Vaccines, Combined